|
|
Volumn , Issue , 2013, Pages
|
|
Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
CEDIRANIB;
QUINAZOLINE DERIVATIVE;
TUMOR PROTEIN;
VASCULOTROPIN;
VASCULOTROPIN RECEPTOR;
ANTAGONISTS AND INHIBITORS;
BIOLOGICAL MODEL;
BONE MARROW CELL;
BRAIN NEOPLASMS;
CELL HYPOXIA;
CLINICAL TRIAL (TOPIC);
DISEASE COURSE;
DRUG ANTAGONISM;
DRUG EFFECTS;
DRUG RESISTANCE;
DRUG SCREENING;
GLIOBLASTOMA;
HUMAN;
METABOLISM;
NEOVASCULARIZATION, PATHOLOGIC;
PATHOPHYSIOLOGY;
PATIENT SELECTION;
PHYSIOLOGY;
SALVAGE THERAPY;
TUMOR MICROENVIRONMENT;
VASCULARIZATION;
ANGIOGENESIS INHIBITORS;
ANTINEOPLASTIC AGENTS;
BEVACIZUMAB;
BRAIN NEOPLASMS;
CELL HYPOXIA;
CLINICAL TRIALS AS TOPIC;
DISEASE PROGRESSION;
DRUG ANTAGONISM;
DRUG RESISTANCE, NEOPLASM;
DRUG SCREENING ASSAYS, ANTITUMOR;
GLIOBLASTOMA;
HUMANS;
MODELS, BIOLOGICAL;
MYELOID CELLS;
NEOPLASM PROTEINS;
NEOVASCULARIZATION, PATHOLOGIC;
PATIENT SELECTION;
QUINAZOLINES;
RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;
SALVAGE THERAPY;
TUMOR MICROENVIRONMENT;
VASCULAR ENDOTHELIAL GROWTH FACTORS;
|
|
EID: 84952332634
PISSN: None
EISSN: 15488756
Source Type: Journal
DOI: 10.1200/EdBook_AM.2013.33.e71 Document Type: Review |
|
Times cited : (9)
|
|
References (0)
|